Novocure Reports CE Mark Approval of Optune Lua for Metastatic NSCLC (mNSCLC)
Shots:
- Novocure has reported CE Mark approval of Optune Lua for mNSCLC adults progressed on Pt-based regimen based on P-III (LUNAR) trial assessing the treatment vs PD-1/PD-L1 inhibitors/docetaxel alone; launch in Germany is expected in coming wks.
- Trial showed improved OS (1EP), with an mOS of 13.2 vs 9.9mos. with treatment vs PD-1/PD-L1 inhibitors/docetaxel, 18.5 vs 10.8mos. with Optune Lua & PD-1/PD-L1 inhibitor vs PD-1/PD-L1 inhibitor & 11.1 vs 8.7mos. with Optune Lua & docetaxel vs docetaxel
- As a CE Mark condition, TTFields concomitant will be assessed with docetaxel in 180 mNSCLC pts over 12mos. to evaluate OS, comparing results to a matched control group treated with docetaxel alone
Ref: Novocure | Image: Novocure
Related News:- Novocure’s Optune Lua Receives the US FDA’s Nod for Treating Metastatic Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
